Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.

Responsive image


Gilead Sciences

Gilead Sciences, Inc.
Company typePublic
Industry
FoundedJune 22, 1987 (1987-06-22)
FounderMichael L. Riordan
HeadquartersFoster City, California, United States
Area served
Worldwide
Key people
Products
RevenueDecrease US$27.12 billion (2023)
Increase US$7.605 billion (2023)
Increase US$5.613 billion (2023)
Total assetsDecrease US$62.13 billion (2023)
Total equityIncrease US$22.83 billion (2023)
Number of employees
c. 18,000 (2023)
Websitegilead.com
Footnotes / references
[1]

Gilead Sciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.

Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade.

In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs.

The company continued its growth in the 2010s. However, it came under heavy scrutiny over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world.[2][3][4][5][6]

  1. ^ "Gilead Sciences, Inc. 2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 23, 2024.
  2. ^ Cite error: The named reference WSJ2019 was invoked but never defined (see the help page).
  3. ^ Cite error: The named reference Stanton2 was invoked but never defined (see the help page).
  4. ^ Cite error: The named reference Silverman was invoked but never defined (see the help page).
  5. ^ Cite error: The named reference Bloomberg2015 was invoked but never defined (see the help page).
  6. ^ Cite error: The named reference WaPo2019a was invoked but never defined (see the help page).

Previous Page Next Page






جلعاد للعلوم Arabic جيلياد ساينسز ARZ قیلیاد AZB Gilead Sciences Catalan Gilead Sciences Czech Gilead Sciences Danish Gilead Sciences German Gilead Sciences Spanish Gilead Sciences EU گیلیاد FA

Responsive image

Responsive image